Your browser doesn't support javascript.
loading
Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group.
Rush, Eric; Brandi, Maria Luisa; Khan, Aliya; Ali, Dalal S; Al-Alwani, Hatim; Almonaei, Khulod; Alsarraf, Farah; Bacrot, Severine; Dahir, Kathryn M; Dandurand, Karel; Deal, Chad; Ferrari, Serge Livio; Giusti, Francesca; Guyatt, Gordon; Hatcher, Erin; Ing, Steven W; Javaid, Muhammad Kassim; Khan, Sarah; Kocijan, Roland; Lewiecki, E Michael; Linglart, Agnes; M'Hiri, Iman; Marini, Francesca; Nunes, Mark E; Rockman-Greenberg, Cheryl; Roux, Christian; Seefried, Lothar; Starling, Susan R; Ward, Leanne; Yao, Liang; Brignardello-Petersen, Romina; Simmons, Jill H.
Afiliação
  • Rush E; Division of Clinical Genetics, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, USA. etrush@cmh.edu.
  • Brandi ML; Department of Pediatrics, University of Missouri - Kansas City School of Medicine, 2401 Gillham Road, Kansas City, MO, USA. etrush@cmh.edu.
  • Khan A; Division of Endocrinology, Metabolism, Osteoporosis, and Genetics, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA. etrush@cmh.edu.
  • Ali DS; F.I.R.M.O. Italian Foundation for the Research on Bone Diseases, Florence, Italy.
  • Al-Alwani H; Donatello Bone Clinic, Villa Donatello Hospital, Florence, Italy.
  • Almonaei K; Division of Endocrinology and Metabolism, McMaster University, Hamilton, Canada.
  • Alsarraf F; Division of Endocrinology and Metabolism, McMaster University, Hamilton, Canada.
  • Bacrot S; Division of Endocrinology and Metabolism, McMaster University, Hamilton, Canada.
  • Dahir KM; Division of Endocrinology and Metabolism, McMaster University, Hamilton, Canada.
  • Dandurand K; Division of Endocrinology and Metabolism, McMaster University, Hamilton, Canada.
  • Deal C; Department of Genetics, Centre Hospitalier de Versailles, Hôpital André Mignot, Versailles, France.
  • Ferrari SL; Division of Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Giusti F; Department of Medicine, Endocrinology and Metabolism, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Guyatt G; Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, The Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Hatcher E; Division of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
  • Ing SW; Donatello Bone Clinic, Villa Donatello Hospital, Florence, Italy.
  • Javaid MK; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.
  • Khan S; Neuromuscular Clinic, McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, Canada.
  • Kocijan R; Division of Endocrinology, Diabetes, & Metabolism, Ohio State University Wexner Medical Center, Columbus, USA.
  • Lewiecki EM; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Linglart A; Bone Research and Education Centre, Oakville, ON, Canada.
  • M'Hiri I; 1st Medical Department, Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of OEGK and AUVA, Trauma Centre Meidling, Hanusch Hospital, 1140, Vienna, Austria.
  • Marini F; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
  • Nunes ME; APHP, Bicêtre Paris-Sud, University Paris Sud, Paris-Saclay, Le Kremlin Bicêtre, Paris, France.
  • Rockman-Greenberg C; Bone Research and Education Centre, Oakville, ON, Canada.
  • Roux C; F.I.R.M.O. Italian Foundation for the Research on Bone Diseases, Florence, Italy.
  • Seefried L; Division of Medical Genetics and Metabolism, Valley Children's HealthCare, Madera, CA, USA.
  • Starling SR; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.
  • Ward L; Rheumatology Department, Hospital Pasteur 2 CHU, 06000, Nice, France.
  • Yao L; Inserm, CNRS, iBV, Université Côte d'Azur, 06000, Nice, France.
  • Brignardello-Petersen R; Musculoskeletal Center Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.
  • Simmons JH; Division of Clinical Genetics, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, USA.
Osteoporos Int ; 35(1): 1-10, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37982855
ABSTRACT
Hypophosphatasia (HPP) is a rare inborn error of metabolism that presents variably in both age of onset and severity. HPP is caused by pathogenic variants in the ALPL gene, resulting in low activity of tissue nonspecific alkaline phosphatase (TNSALP). Patients with HPP tend have a similar pattern of elevation of natural substrates that can be used to aid in diagnosis. No formal diagnostic guidelines currently exist for the diagnosis of this condition in children, adolescents, or adults. The International HPP Working Group is a comprised of a multidisciplinary team of experts from Europe and North America who have expertise in the diagnosis and management of patients with HPP. This group reviewed 93 papers through a Medline, Medline In-Process, and Embase search for the terms "HPP" and "hypophosphatasia" between 2005 and 2020 and that explicitly address either the diagnosis of HPP in children, clinical manifestations of HPP in children, or both. Two reviewers independently evaluated each full-text publication for eligibility and studies were included if they were narrative reviews or case series/reports that concerned diagnosis of pediatric HPP or included clinical aspects of patients diagnosed with HPP. This review focused on 15 initial clinical manifestations that were selected by a group of clinical experts.The highest agreement in included literature was for pathogenic or likely pathogenic ALPL variant, elevation of natural substrates, and early loss of primary teeth. The highest prevalence was similar, including these same three parameters and including decreased bone mineral density. Additional parameters had less agreement and were less prevalent. These were organized into three major and six minor criteria, with diagnosis of HPP being made when two major or one major and two minor criteria are present.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hipofosfatasia Limite: Adolescent / Adult / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Osteoporos Int Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hipofosfatasia Limite: Adolescent / Adult / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Osteoporos Int Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos